Evotec/$EVO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Evotec
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
- Ticker
- $EVO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 4,379
- Headquarters
- Hamburg, Germany
- Website
- www.evotec.com
Evotec Metrics
BasicAdvanced
$622M
-
-$1.13
1.31
-
Price and volume
Market cap
$622M
Beta
1.31
52-week high
$3.87
52-week low
$1.33
Average daily volume
100K
Financial strength
Current ratio
2.322
Quick ratio
2.003
Long term debt to equity
0.65
Total debt to equity
0.751
Profitability
EBITDA (TTM)
-66.225
Gross margin (TTM)
10.27%
Net profit margin (TTM)
-25.16%
Operating margin (TTM)
-17.96%
Effective tax rate (TTM)
-10.96%
Revenue per employee (TTM)
$177,240
Management effectiveness
Return on assets (TTM)
-4.92%
Return on equity (TTM)
-25.07%
Valuation
Price to revenue (TTM)
0.377
Price to book
0.88
Price to tangible book (TTM)
1.68
Price to free cash flow (TTM)
-1.982
Free cash flow yield (TTM)
-50.45%
Free cash flow per share (TTM)
-0.853
Growth
Revenue change (TTM)
-5.03%
Earnings per share change (TTM)
13.04%
3-year revenue growth (CAGR)
-4.35%
10-year revenue growth (CAGR)
16.20%
3-year earnings per share growth (CAGR)
23.73%
10-year earnings per share growth (CAGR)
22.98%
What the Analysts think about Evotec
Analyst ratings (Buy, Hold, Sell) for Evotec stock.
Analyst projections of the future price of Evotec stock.
Bulls say / Bears say
D&PD base-business net sales rose 24% in the first nine months, while the customer base and inbound leads also grew. That suggests improving demand in Evotec’s core research services, even as group revenue fell. (Evotec)
Project Horizon had delivered more than 20% of its €75 million annual savings target by September, ahead of the contribution planned for 2026. If the remaining cuts are delivered, they could help restore profitability. (Evotec)
Vertex selected Just – Evotec Biologics for commercial manufacturing of povetacicept, giving Evotec a concrete route to scale its biologics platform. Evotec plans to add a manufacturing train at Redmond to support this and other customer work. (Evotec)
Nine-month revenue fell 13.1% year on year, and adjusted EBITDA loss widened to €44.3 million from €16.9 million. The latest full-year outlook still implies a substantial adjusted EBITDA loss. (Evotec)
Operating cash outflow reached €155 million in the first nine months, while liquidity fell to €400.9 million and financial liabilities rose to €481.8 million. That combination leaves less room for error if the recovery takes longer than expected. (StockTitan)
Evotec cut its 2026 revenue outlook from €700–780 million to €570–610 million and moved from forecast adjusted EBITDA profit to a loss. The company attributed the downgrade largely to delayed partnership deals and milestones, highlighting the risk that timing shifts can sharply affect results. (Evotec)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
Evotec Financial Performance
Revenues and expenses
Evotec Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.